Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience

Published:2023-10-23 Issue: Volume: Page:
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Castelli Alessandro¹,Lanzafame Massimiliano¹^ORCID,Morra Matteo²,Bertoldi Marco¹,Delama Andrea¹,Fait Daniela¹,Vento Sandro³

Affiliation:

1. Unit of Infectious Diseases, Dipartimento di Area Medica, “Santa Chiara” Hospital, Trento, Italy.

2. Unit of Infectious Diseases, Azienda Ospedaliera Universitaria Integrata, “G.B. Rossi” Hospital, Verona, Italy.

3. Faculty of Medicine, University of Puthisastra, Phnom Penh, Cambodia.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2023.0070

Reference9 articles.

1. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

2. The propensity for long‐acting cabotegravir and rilpivirine every 2 months among HIV‐infected people eligible for treatment

3. Long-acting drugs: people’s expectations and physicians’ preparedness. Are we readying to manage it? An Italian survey

4. Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change Version

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP